A recent analysis of the ACCESS randomized trial reveals molecular pathways that enhance the efficacy of clarithromycin in treating community-acquired pneumonia. This study provides insights into the drug's mechanism, potentially guiding future therapeutic strategies.
molecular pathways driving clarithromycin benefit in community acquired pneumonia analysis of the access randomised trial
Original title: “Molecular pathways driving clarithromycin benefit in community-acquired pneumonia: analysis of the ACCESS randomised trial.”